Lactobacillus rhamnosus GG
Research reviewed: Up until 03/2026
Lactobacillus rhamnosus GG (Lacticaseibacillus rhamnosus GG) is a dietary supplement with 8 published peer-reviewed studies involving 1,965 participants, researched for Diarrhea Prevention & Treatment, IBS & Gut Health, Immune Function.
Evidence at a Glance
Strength is scored by study design, sample size, study type, and outcomes
Diarrhea Prevention & Treatment
ModerateIBS & Gut Health
StrongImmune Function
ModerateResearch Visualised
Visual breakdown of the clinical data.
Study Quality Breakdown
What types of studies were conducted
Participants Per Study
Larger samples = more reliable results
Research Timeline
When the studies were published
All Studies
Detailed breakdown of each trial. Click to expand.
Diarrhea Prevention & Treatment
To evaluate probiotics for prevention and treatment of acute infectious diarrhea in children.
Study Type
Cochrane systematic review
Purpose
To evaluate probiotics for prevention and treatment of acute infectious diarrhea in children.
Dose
Various LGG doses (5-40 billion CFU/day)
Participants
Systematic review of 63 trials, >8000 participants
Duration
Various
Results
LGG significantly reduced duration of diarrhea by approximately 1 day and reduced risk of diarrhea lasting ≥4 days. Effects were most pronounced in children.
How They Measured It
Duration and severity of diarrhea episodes
To evaluate LGG for prevention of antibiotic-associated diarrhea in children.
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To evaluate LGG for prevention of antibiotic-associated diarrhea in children.
Dose
10 billion CFU/day
Participants
188 children aged 6 months to 10 years
Duration
Duration of antibiotic course
Results
LGG significantly reduced the incidence of antibiotic-associated diarrhea (5% vs 16% placebo, p<0.05).
How They Measured It
Incidence of diarrhea during antibiotic treatment
To assess LGG for treatment of acute gastroenteritis in European children.
Study Type
Multi-center randomised controlled trial
Purpose
To assess LGG for treatment of acute gastroenteritis in European children.
Dose
10 billion CFU twice daily
Participants
571 children with acute gastroenteritis
Duration
5 days treatment
Results
LGG reduced the duration of diarrhea by approximately 24 hours compared to placebo. Hospital stay was also shorter in the LGG group.
How They Measured It
Duration of diarrhea, hospitalization length
IBS & Gut Health
To evaluate LGG for symptom relief in irritable bowel syndrome.
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To evaluate LGG for symptom relief in irritable bowel syndrome.
Dose
6 billion CFU twice daily
Participants
104 IBS patients
Duration
8 weeks
Results
LGG significantly reduced abdominal distension and improved stool consistency. Moderate improvements in overall IBS symptoms were noted.
How They Measured It
IBS symptom scores, abdominal pain frequency
To assess efficacy of LGG in functional abdominal pain in children.
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To assess efficacy of LGG in functional abdominal pain in children.
Dose
10 billion CFU twice daily
Participants
141 children aged 5-14 years with functional abdominal pain
Duration
8 weeks
Results
LGG significantly reduced frequency and intensity of abdominal pain episodes compared to placebo. Treatment success rate was 72% vs 53% placebo.
How They Measured It
Pain intensity (Wong-Baker FACES), frequency of pain episodes
Immune Function
To evaluate the effect of LGG on incidence and severity of respiratory infections in children attending daycare.
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To evaluate the effect of LGG on incidence and severity of respiratory infections in children attending daycare.
Dose
10 billion CFU/day in milk
Participants
571 children aged 1-6 in daycare centers
Duration
7 months
Results
LGG reduced the incidence of respiratory infections by 17% and reduced antibiotic treatments by 19% compared to placebo.
How They Measured It
Incidence of respiratory infections, days absent from daycare
To assess LGG supplementation on immune response and infection rates in preterm infants.
Study Type
Randomised controlled trial
Purpose
To assess LGG supplementation on immune response and infection rates in preterm infants.
Dose
1 billion CFU/day
Participants
315 preterm infants
Duration
Until discharge
Results
LGG supplementation significantly reduced the incidence of NEC stage ≥2 and late-onset sepsis in preterm infants.
How They Measured It
Incidence of necrotizing enterocolitis (NEC), sepsis
To review evidence on LGG for prevention of infections in children.
Study Type
Systematic review
Purpose
To review evidence on LGG for prevention of infections in children.
Dose
Various
Participants
Review of 12 RCTs
Duration
Various
Results
Moderate evidence supporting LGG for reduction in respiratory and gastrointestinal infections in children, with strongest evidence for daycare settings.
How They Measured It
Pooled analysis across included studies
Frequently Asked Questions
Common questions about Lactobacillus rhamnosus GG research
There are currently 8 peer-reviewed studies on Lactobacillus rhamnosus GG (Lacticaseibacillus rhamnosus GG), involving 1,965 total participants. Research covers Diarrhea prevention, Gut health, Pediatric GI health and 1 more areas. The overall evidence strength is rated as Strong.
The evidence is currently rated as "Strong Evidence". This rating is based on study design quality (randomisation, blinding, placebo controls), sample sizes, study types (6 human studies), and reported outcomes.
Lactobacillus rhamnosus GG has been researched for: Diarrhea prevention, Gut health, Pediatric GI health, Immune support. Each area has its own body of evidence which you can explore in the study breakdowns above.
Yes, 6 out of 8 studies are human trials. Human trials carry more weight in our evidence scoring system.
Similar Supplements
Other supplements researched for similar health goals
